A five-institution Saudi consortium spanning three cities published a 44-patient Dravet syndrome stiripentol study, evidence of how concentrated GCC pediatric epilepsy expertise for this disease actually is.
GCC Dravet syndrome expertise concentrates around a small number of pediatric neurology centres, not a broad national field. A 2025 multi-center study spanning five institutions, the National Neuroscience Institute at King Fahad Medical City, King Abdullah Specialist Children's Hospital, King Faisal Specialist Hospital and Research Center's Riyadh and Jeddah sites, and King Fahad Specialist Hospital in Dammam, tracked 44 SCN1A-confirmed Dravet syndrome patients on stiripentol therapy. Twenty-five patients showed a significant seizure reduction; twelve showed a mild to moderate one. That kind of coordinated, cross-city publication does not happen without an established referral and collaboration network. Our KOL Universe gate (K1) starts by mapping exactly this kind of institutional concentration before any single physician is scored.
That structure changes how AXLRx tiers influence in the GCC. A pediatric neurologist publishing as part of a five-institution national consortium carries different scientific weight than one working in isolation, and our Tier Classification gate (K2) scores that distinction directly, alongside SCN1A-genotyping capability and guideline-relevant institutional roles. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over prescribing peers, which is exactly what the K1-K6 gate structure is built to prevent.
The Saudi Dravet syndrome consortium — five institutions, three cities
| Institution | City | Role in Consortium |
|---|---|---|
| National Neuroscience Institute, King Fahad Medical City | Riyadh | Lead site, pediatric neurology |
| King Abdullah Specialist Children's Hospital (National Guard Health Affairs) | Riyadh | Pediatric neurology division |
| King Faisal Specialist Hospital and Research Center | Riyadh | Neuroscience department |
| King Faisal Specialist Hospital and Research Center | Jeddah | Pediatrics department |
| King Fahad Specialist Hospital | Dammam | Pediatric neurology division |
Sources: Almuatiri AM et al., Stiripentol safety profile and efficacy in cases of SCN1A-related Dravet syndrome, multi-center experience, Saudi Arabia, Neurosciences (Riyadh) 2025;30(3):209-215.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The five-institution, three-city Saudi consortium structure
- institutional concentration as a KOL-tiering signal
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- SCN1A-genotyping capability and institutional-role weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live publication and institutional-affiliation cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the five-institution Saudi consortium case before the rest of the workbook is built out
- Every GCC Dravet syndrome KOL sized and sourced from publication and institutional-affiliation data
- The five-institution Saudi consortium as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescriber
- Scientific-influence scoring across consortium membership and SCN1A-genotyping capability
- What separates a Tier 1 KOL from a high-volume community prescriber
- Influence inputs: multi-center publication authorship, genotyping capability, institutional role
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across Riyadh, Jeddah, Dammam, and the rest of the GCC
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active beyond Saudi Arabia, across the wider GCC
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.
GCC Dravet syndrome KOL sources: Almuatiri AM et al., Stiripentol safety profile and efficacy in cases of SCN1A-related Dravet syndrome, multi-center experience, Saudi Arabia, Neurosciences (Riyadh) 2025, and the institutional affiliations named in that publication.
- Consortium institution list and patient counts verified against Almuatiri AM et al., Neurosciences (Riyadh) 2025;30(3):209-215
- Seizure-reduction outcome figures verified against the same publication
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC Dravet syndrome specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.